Similar articles

• A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

  Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. Gatcliffe TA, et al. Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1. Gynecol Oncol. 2009. PMID: 18977518 Clinical Trial.
• Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.

  Kendrick JE, Straughn JM Jr, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ. Kendrick JE, et al. Gynecol Oncol. 2008 Mar;108(3):591-7. doi: 10.1016/j.ygyno.2007.11.039. Epub 2008 Jan 4. Gynecol Oncol. 2008. PMID: 18177927
• Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.

  Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH, Chen TH. Liu MT, et al. Eur J Cancer Care (Engl). 2008 Mar;17(2):174-81. doi: 10.1111/j.1365-2354.2007.00831.x. Eur J Cancer Care (Engl). 2008. PMID: 18302655
• Chemotherapy for recurrent cervical cancer.

  Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Pectasides D, et al. Cancer Treat Rev. 2008 Nov;34(7):603-13. doi: 10.1016/j.ctrv.2008.05.006. Epub 2008 Jul 26. Cancer Treat Rev. 2008. PMID: 18657909 Review.
• Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.

  Tewari KS, Monk BJ. Tewari KS, et al. Semin Oncol. 2009 Apr;36(2):170-80. doi: 10.1053/j.seminoncol.2008.12.008. Semin Oncol. 2009. PMID: 19332251 Review.